A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients

被引:19
作者
Biros, E
Kohút, A
Biros, I
Kalina, I
Bogyiová, E
Stubna, J
机构
[1] Safarik Univ, Sch Med, Dept Med Biol, Kosice 04066, Slovakia
[2] Acad Sci Czech Republ, Inst Expt Med, Lab Genet Ecotoxicol, Prague 14220 4, Czech Republic
[3] Safarik Univ, Sch Med, Dept Pharmacol, Tr SNP 1, Kosice 04066, Slovakia
[4] Univ Queensland, AEGRC, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia
[5] Safarik Univ, Sch Med, Inst Med Microbiol, Kosice 04180, Slovakia
[6] Teaching Hosp, Dept TB & Resp Dis, Kosice 04066, Slovakia
关键词
p53; polymorphism; apoptosis; lung cancer;
D O I
10.1016/S0169-5002(01)00446-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The p53 protein acts as a checkpoint in the cell cycle, either preventing or initiating apoptosis. Since cancer is the unchecked proliferation of cells, p53s role is critical. Thus, we have sought a link between the p53 polymorphisms and apoptosis. Wild-type p53 tumor suppressor gene exhibits several common single nucleotide polymorphisms (SNP) both in coding and non-coding regions. We foe-used on two of them, the p53 BstUI SNP on the fourth exon, and the p53 MspI SNP on the sixth intron. We investigated a presence of these two polymorphisms in relation to apoptosis of white blood cells in lung cancer patients and healthy controls. We found that both the p53 BstUI and the p53 MspI homozygous genotypes A2/A2 were associated with significantly higher content of apoptotic white blood cells in comparison to relevant A2/A1 heterozygous genotypes (P<0.001, 0.05) in lung cancer patients. These observations suggest that the p53 BstUI and the p53 MspI SNPs may play a certain role in p53 dependent apoptotic pathway. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:231 / 235
页数:5
相关论文
共 31 条
[1]   Regulation of p53 stability [J].
Ashcroft, M ;
Vousden, KH .
ONCOGENE, 1999, 18 (53) :7637-7643
[2]   Variations of p53 in cultured fibroblasts of patients with lung cancer who have a presumed genetic predisposition [J].
Auer, H ;
Warncke, K ;
Nowak, D ;
Koops, F ;
Jaeger, U ;
Kurzbauer, R ;
Ruediger, HW .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (03) :278-282
[3]   P53 POLYMORPHISMS AND HAPLOTYPES IN LUNG-CANCER [J].
BIRGANDER, R ;
SJALANDER, A ;
RANNUG, A ;
ALEXANDRIE, AK ;
SUNDBERG, MI ;
SEIDEGARD, J ;
TORNLING, G ;
BECKMAN, G ;
BECKMAN, L .
CARCINOGENESIS, 1995, 16 (09) :2233-2236
[4]   Germ line polymorphisms of the tumor suppressor gene p53 and lung cancer [J].
Biros, E ;
Kalina, I ;
Kohút, A ;
Stubna, J ;
Salagovic, J .
LUNG CANCER, 2001, 31 (2-3) :157-162
[5]   Regulation of p53 downstream genes [J].
El-Deiry, WS .
SEMINARS IN CANCER BIOLOGY, 1998, 8 (05) :345-357
[6]  
Fan R, 2000, CANCER EPIDEM BIOMAR, V9, P1037
[7]   The complexity of p53 modulation: emerging patterns from divergent signals [J].
Giaccia, AJ ;
Kastan, MB .
GENES & DEVELOPMENT, 1998, 12 (19) :2973-2983
[8]   Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies [J].
Harris, CC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) :1442-1455
[9]   MOLECULAR-BASIS FOR HETEROGENEITY OF THE HUMAN P53-PROTEIN [J].
HARRIS, N ;
BRILL, E ;
SHOHAT, O ;
PROKOCIMER, M ;
WOLF, D ;
ARAI, N ;
ROTTER, V .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (12) :4650-4656
[10]  
JIN X, 1995, CARCINOGENESIS, V9, P2205